Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Infectious Diseases›Cholera
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Cholera

Infectious Diseases · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is vibrio cholerae.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (751 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is vibrio cholerae. This condition can lead to severe dehydration in a matter of hours unless quickly treated.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Choleras; Vibrio cholerae Infection; Infections, Vibrio cholerae; Infection, Vibrio cholerae; Vibrio cholerae Infections.

Where it fits in the MeSH classification

Broader topics
Vibrio Infections
See also
Cholera Morbus

Related concepts

  • Vibrio Cholerae

Research landscape

PubMed indexes 9,873 records tagged with the MeSH heading “Cholera” (counts retrieved 2026-10-29). 1,244 of them (12.6%) were published from 2020 onward, and the busiest period so far is through 1999 with 5,186 records.

Reviews account for 847 records (8.6%) and meta-analyses for 40. Randomized controlled trials number 220 (2.2%) as a share of all records on the topic.

PubMed records by publication periodthrough 1999: 5,186 records; 2000-2009: 1,353 records; 2010-2019: 2,090 records; 2020 onward: 1,244 records5,186through 19991,3532000-20092,0902010-20191,2442020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19995,186
2000-20091,353
2010-20192,090
2020 onward1,244
Share of records by publication typeReviews: 8.6 percent; Meta-analyses: 0.4 percent; Randomized controlled trials: 2.2 percentReviews8.6% (847)Meta-analyses0.4% (40)Randomized controlled trials2.2% (220)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 9,873 PubMed records
TypeRecordsShare
Reviews8478.6%
Meta-analyses400.4%
Randomized controlled trials2202.2%

Method: PubMed query "Cholera"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in infectious diseases

Infectious disease evidence combines microbiology, epidemiology and clinical trials. Laboratory studies identify pathogens and how they cause harm; surveillance and outbreak investigations describe who is affected and how infection spreads; trials establish whether treatments and vaccines work. Results depend on place and time, because pathogens evolve and resistance patterns and population immunity change. Check when and where the data were collected, how cases were defined and how up to date the evidence is.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Cholera outbreaks in sub-Saharan Africa during 2010-2019: a descriptive analysis
Zheng Q, Luquero FJ, Ciglenecki I, Wamala JF, Abubakar A, Welo P, et al.
2022Research article
Design not recorded in structured metadata
58cc by
PMID 35605949 · DOI · PMC9439956
Genomic epidemiology reveals multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen
Lassalle F, Al-Shalali S, Al-Hakimi M, Njamkepo E, Bashir IM, Dorman MJ, et al.
2023Research article
Design not recorded in structured metadata
51cc by
PMID 37770747 · DOI · PMC10539172
The Vibrio cholerae Seventh Pandemic Islands act in tandem to defend against a circulating phage
O'Hara BJ, Alam M, Ng WL
2022Research article
Design not recorded in structured metadata
46cc by
PMID 36026491 · DOI · PMC9455884
Multicountry genomic analysis underscores regional cholera spread in Africa
Mboowa G, Matteson NL, Tanui CK, Kasonde M, Kamwiziku GK, Akanbi OA, et al.
2026Research article
Design not recorded in structured metadata
10cc by
PMID 41663395 · DOI · PMC13000271

Cholera outbreaks in sub-Saharan Africa during 2010-2019: a descriptive analysis [1]

Research article Zheng Q, Luquero FJ, Ciglenecki I, Wamala JF, Abubakar A, Welo P, et al. · · 2022 · cited 58 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundCholera remains a public health threat but is inequitably distributed across sub-Saharan Africa.
Closing excerpt
ConclusionsThis study provides a baseline from which the progress toward cholera control and essential statistics to inform outbreak management in sub-Saharan Africa can be monitored.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (193 words)

BackgroundCholera remains a public health threat but is inequitably distributed across sub-Saharan Africa. Lack of standardized reporting and inconsistent outbreak definitions limit our understanding of cholera outbreak epidemiology.MethodsFrom a database of cholera incidence and mortality, we extracted data from sub-Saharan Africa and reconstructed outbreaks of suspected cholera starting in January 2010 to December 2019 based on location-specific average weekly incidence rate thresholds. We then described the distribution of key outbreak metrics.ResultsWe identified 999 suspected cholera outbreaks in 744 regions across 25 sub-Saharan African countries. The outbreak periods accounted for 1.8 billion person-months (2% of the total during this period) from January 2010 to January 2020. Among 692 outbreaks reported from second-level administrative units (e.g., districts), the median attack rate was 0.8 per 1000 people (interquartile range (IQR), 0.3-2.4 per 1000), the median epidemic duration was 13 weeks (IQR, 8-19), and the median early outbreak reproductive number was 1.8 (range, 1.1-3.5). Larger attack rates were associated with longer times to outbreak peak, longer epidemic durations, and lower case fatality risks.ConclusionsThis study provides a baseline from which the progress toward cholera control and essential statistics to inform outbreak management in sub-Saharan Africa can be monitored.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 35605949 · DOI · PMC9439956

Genomic epidemiology reveals multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen [2]

Research article Lassalle F, Al-Shalali S, Al-Hakimi M, Njamkepo E, Bashir IM, Dorman MJ, et al. · · 2023 · cited 51 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Since 2016, Yemen has been experiencing the largest cholera outbreak in modern history.
Closing excerpt
Stable co-occurrence of the IncC plasmid with the SXT family of integrative and conjugative element in the 7PET background has major implications for cholera control, highlighting the importance of genomic epidemiological surveillance to limit MDR spread.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (154 words)

Since 2016, Yemen has been experiencing the largest cholera outbreak in modern history. Multidrug resistance (MDR) emerged among Vibrio cholerae isolates from cholera patients in 2018. Here, to characterize circulating genotypes, we analysed 260 isolates sampled in Yemen between 2018 and 2019. Eighty-four percent of V. cholerae isolates were serogroup O1 belonging to the seventh pandemic El Tor (7PET) lineage, sub-lineage T13, whereas 16% were non-toxigenic, from divergent non-7PET lineages. Treatment of severe cholera with macrolides between 2016 and 2019 coincided with the emergence and dominance of T13 subclones carrying an incompatibility type C (IncC) plasmid harbouring an MDR pseudo-compound transposon. MDR plasmid detection also in endemic non-7PET V. cholerae lineages suggested genetic exchange with 7PET epidemic strains. Stable co-occurrence of the IncC plasmid with the SXT family of integrative and conjugative element in the 7PET background has major implications for cholera control, highlighting the importance of genomic epidemiological surveillance to limit MDR spread.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37770747 · DOI · PMC10539172

The Vibrio cholerae Seventh Pandemic Islands act in tandem to defend against a circulating phage [3]

Research article O'Hara BJ, Alam M, Ng WL · · 2022 · cited 46 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The current circulating pandemic El Tor biotype of Vibrio cholerae has persisted for over sixty years and is characterized by its acquisition of two unique genomic islands called the Vibrio Seventh Pandemic Islands 1 and 2 (VSP-I and VSP-II).
Closing excerpt
cholerae and highlights the key regulatory and mechanistic insights that can be gained by studying anti-phage systems in their native contexts.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (231 words)

The current circulating pandemic El Tor biotype of Vibrio cholerae has persisted for over sixty years and is characterized by its acquisition of two unique genomic islands called the Vibrio Seventh Pandemic Islands 1 and 2 (VSP-I and VSP-II). However, the functions of most of the genes on VSP-I and VSP-II are unknown and the advantages realized by El Tor through these two islands are not clear. Recent studies have broadly implicated these two mobile genetic elements with phage defense. Still, protection against phage infection through these islands has not been observed directly in any V. cholerae El Tor biotype. Here we report the isolation of a circulating phage from a cholera patient stool sample and demonstrate that propagation of this phage in its native host is inhibited by elements in both VSP-I and VSP-II, providing direct evidence for the role of these genomic islands in phage defense. Moreover, we show that these defense systems are regulated by quorum sensing and active only at certain cell densities. Finally, we have isolated a naturally occurring phage variant that is resistant to the defense conferred by the VSP islands, illustrating the countermeasures used by phages to evade these defense mechanisms. Together, this work demonstrates a functional role for the VSPs in V. cholerae and highlights the key regulatory and mechanistic insights that can be gained by studying anti-phage systems in their native contexts.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36026491 · DOI · PMC9455884

Multicountry genomic analysis underscores regional cholera spread in Africa [4]

Research article Mboowa G, Matteson NL, Tanui CK, Kasonde M, Kamwiziku GK, Akanbi OA, et al. · · 2026 · cited 10 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Cholera remains a significant public health burden in many countries in sub-Saharan Africa, though the exact mechanisms of bacterial emergence and spread remain largely undefined.
Closing excerpt
Overall, our findings emphasize the importance of regionally coordinated cross-border surveillance and interventions, while also demonstrating the critical role of locally generated genomic data in understanding the spread of cholera in Africa.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (173 words)

Cholera remains a significant public health burden in many countries in sub-Saharan Africa, though the exact mechanisms of bacterial emergence and spread remain largely undefined. We generated genomic data from 763 Vibrio cholerae O1 isolates predominantly collected between 2019-2024 to create the largest dataset of V. cholerae genomes sequenced locally in Africa. This dataset enabled us to interrogate recent patterns of spread, including the rapid circulation of the AFR15 lineage associated with unusually large outbreaks in Southern Africa. We provide evidence for the movement of the AFR15 lineage into new African Union Member States and confirm previously observed differences in V. cholerae transmission dynamics in West versus East Africa, though cross-border transmission is prevalent on both sides of the continent. Despite observed differences, evolutionary processes are similar across lineages and we find no evidence for significant changes in antimicrobial resistance genotypes. Overall, our findings emphasize the importance of regionally coordinated cross-border surveillance and interventions, while also demonstrating the critical role of locally generated genomic data in understanding the spread of cholera in Africa.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41663395 · DOI · PMC13000271

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Cholera [5]
    Kaper JB, Morris JG, Levine MM · Clin Microbiol Rev · 1995 · cited 1,008 times (Europe PMC)
  • Research article Cholera [6]
    Sack DA, Sack RB, Nair GB, Siddique AK · Lancet · 2004 · cited 671 times (Europe PMC)
  • Research article Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae [7]
    Faruque SM, Albert MJ, Mekalanos JJ · Microbiol Mol Biol Rev · 1998 · cited 630 times (Europe PMC)
  • Research article Cholera [8]
    Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB · Lancet · 2012 · cited 458 times (Europe PMC)
  • Research article Cholera [9]
    Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J · Lancet · 2017 · cited 312 times (Europe PMC)
  • Research article Vibrio cholerae and cholera: out of the water and into the host [10]
    Reidl J, Klose KE · FEMS Microbiol Rev · 2002 · cited 275 times (Europe PMC)

References

  1. Zheng Q, Luquero FJ, Ciglenecki I, Wamala JF, Abubakar A, Welo P, et al.. Cholera outbreaks in sub-Saharan Africa during 2010-2019: a descriptive analysis. . 2022. PMID 35605949 · DOI · PMC9439956
  2. Lassalle F, Al-Shalali S, Al-Hakimi M, Njamkepo E, Bashir IM, Dorman MJ, et al.. Genomic epidemiology reveals multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen. . 2023. PMID 37770747 · DOI · PMC10539172
  3. O'Hara BJ, Alam M, Ng WL. The Vibrio cholerae Seventh Pandemic Islands act in tandem to defend against a circulating phage. . 2022. PMID 36026491 · DOI · PMC9455884
  4. Mboowa G, Matteson NL, Tanui CK, Kasonde M, Kamwiziku GK, Akanbi OA, et al.. Multicountry genomic analysis underscores regional cholera spread in Africa. . 2026. PMID 41663395 · DOI · PMC13000271
  5. Kaper JB, Morris JG, Levine MM. Cholera. Clin Microbiol Rev. 1995. PMID 7704895 · DOI · PMC172849
  6. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet. 2004. PMID 14738797 · DOI
  7. Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae. Microbiol Mol Biol Rev. 1998. PMID 9841673 · DOI · PMC98947
  8. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet. 2012. PMID 22748592 · DOI · PMC3761070
  9. Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. Cholera. Lancet. 2017. PMID 28302312 · DOI
  10. Reidl J, Klose KE. Vibrio cholerae and cholera: out of the water and into the host. FEMS Microbiol Rev. 2002. PMID 12069878 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • AnthraxInfectious Diseases
  • Gram-Negative Bacterial InfectionsInfectious Diseases
  • TetanusInfectious Diseases
  • Buruli UlcerInfectious Diseases
  • DiphtheriaInfectious Diseases
  • Latent TuberculosisInfectious Diseases

All 102 articles in Infectious Diseases →

At a glance

9,873
PubMed records on this heading
13%
published since 2020
847
review articles
220
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • AnthraxInfectious Diseases
  • Gram-Negative Bacterial InfectionsInfectious Diseases
  • TetanusInfectious Diseases
  • Buruli UlcerInfectious Diseases
  • DiphtheriaInfectious Diseases

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support